Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The primary objective of the research project is to determine the change in the psoriasis area and severity index (∆PASI) during twenty four weeks of treatment with a dipeptidyl peptidase-4 inhibitor (Januvia®, 100mg daily, or 50mg daily for participants with moderate kidney disease) in psoriasis patients undergoing narrow-band ultraviolet-B (NB-UVB) light therapy. This will be compared to the ∆PASI of psoriasis patients undergoing NB-UVB light therapy who are allocated randomly to not receive any additional treatment.
Critère d'inclusion
- Psoriasis